Pulmonary Drug Delivery Systems Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Global Pulmonary Drug Delivery Systems Market: By Product Type (Metered Dose Inhaler, Nebulizer, Dry Powder Inhaler), By Technology (Manually Operated Inhalers, Digitally Operated Inhalers), By Disease Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

Pulmonary Drug Delivery Systems Market size is valued at USD 52,670.16 million in 2021 and is expected to reach USD 78,156.36 million by 2028, at a CAGR of 5.8% during the forecast period 2022-2028. Pulmonary drug delivery systems helps to treat diseases such as asthma, cystic fibrosis. The pulmonary route is used in the treatment of various respiratory disorders. The pulmonary drug delivery is gaining popularity owing to its target specificity. The pulmonary drug delivery system delivers the medication thorough the respiratory tract. It is majorly used in the treatment of the conditions such as delivery of locally acting drugs directly to the sites of action. In December 2017, Sunovion receives the U.S. Food and Drug Administration (FDA) approval for the New Drug Application (NDA) for Lonhala Magnair (glycopyrrolate) Inhalation Solution, also known as SUN-101/eFlow, for the long-term, maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Industry trends in the market are evolving, which will aid players in developing successful long-term strategies. Both established and emerging markets have implemented business growth techniques. COVID-19 is an unprecedented worldwide public health crisis that has impacted practically every business, and its long-term repercussions are expected to have an influence on industry growth during the projection period. Our continuous study is enhancing our research approach to guarantee that fundamental COVID-19 concerns and potential solutions are included. The research examines COVID-19 in light of changes in consumer behaviour and demand, purchasing patterns, supply chain re-routing, market dynamics, and government involvement. Pulmonary Drug Delivery Systems Market research report considers the influence of COVID-19 on the market and includes insights, analysis, projections, and predictions.

Pulmonary Drug Delivery Systems Market

MARKET SUMMARY
-
5.8% CAGR
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 5.8%
  • Largest Market– North America
  • Fastest Growing Market– Asia Pacific

Pulmonary Drug Delivery Systems Market

  • The global pulmonary drug delivery systems market is segmented based on the product type, application, and distribution channel.
  • Geographically, global pulmonary drug delivery systems market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
Market Key Players
  • Sunovion Pharmaceuticals Inc. (U.S)
  • Omron Corporation (Japan)
  • Novartis AG (Switzerland)
  • GlaxoSmithKline (U.K)
  • 3M (U.S)
Drivers And Restraints

Pulmonary Drug Delivery Systems Market

Increase in the prevalence of various chronic disease such as chronic pulmonary disease, tuberculosis, and bronchitis are expected to fuel the growth of pulmonary drug delivery systems market. The preference of the non-invasive techniques are witnessing to the growth of market. The minimum dosage requirement is another factor, which creates demand for pulmonary drug delivery systems market. The technological advancements, growing support from the government and non-government organizations, increasing awareness and rising funds are expected to anticipate the growth of the market. However, the government regulatory issues in the approval of the product would hamper the growth of pulmonary drug delivery systems market.


Asia-Pacific Got Significant Share

Pulmonary Drug Delivery Systems Market

Geographically, global pulmonary drug delivery systems market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North Americapulmonary drug delivery systems market is anticipated to expand at robust growth rates due to increase in prevalence of respiratory disorders. The surge in awareness about the modern treatment options and its adoption is expected to create healthy growth opportunities over the forecast period. As per World Health Organization (WHO) statistics, smoking is estimated to cause 71% of the lung cancer deaths and 42% of the chronic respiratory diseases worldwide. Out of the six regions of WHO, Europe was accounted for highest prevalence for smoking i.e., 29 per cent in 2008. The Europe pulmonary drug delivery systems market is expected to show a significant growth over the forecasted period. The Asia Pacific pulmonary drug delivery systems market is predicted to show tremendous growth in the emerging countries such as India and China owing to rising population coupled with increasing prevalence of respiratory disorders.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East
Pulmonary Drug Delivery Systems Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The pulmonary drug delivery systems market is projected to expand at a CAGR of 5.8% during the forecast period.

Asia-Pacific is the fastest-growing region for pulmonary drug delivery systems market

Sunovion Pharmaceuticals Inc., Omron Corporation, Novartis AG, GlaxoSmithKline, 3M


Report

Table Of Content


Report

Company Profile

  • Sunovion Pharmaceuticals Inc. (U.S)
  • AstraZeneca plc (U.K)
  • Omron Corporation (Japan)
  • Novartis AG (Switzerland)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • GlaxoSmithKline (U.K)
  • 3M (U.S)
  • Boehringer Ingelheim GmbH (Germany)

Description

Pulmonary Drug Delivery Systems Market size is valued at USD 52,670.16 million in 2021 and is expected to reach USD 78,156.36 million by 2028, at a CAGR of 5.8% during the forecast period 2022-2028. Pulmonary drug delivery systems helps to treat diseases such as asthma, cystic fibrosis. The pulmonary route is used in the treatment of various respiratory disorders. The pulmonary drug delivery is gaining popularity owing to its target specificity. The pulmonary drug delivery system delivers the medication thorough the respiratory tract. It is majorly used in the treatment of the conditions such as delivery of locally acting drugs directly to the sites of action. In December 2017, Sunovion receives the U.S. Food and Drug Administration (FDA) approval for the New Drug Application (NDA) for Lonhala Magnair (glycopyrrolate) Inhalation Solution, also known as SUN-101/eFlow, for the long-term, maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Industry trends in the market are evolving, which will aid players in developing successful long-term strategies. Both established and emerging markets have implemented business growth techniques. COVID-19 is an unprecedented worldwide public health crisis that has impacted practically every business, and its long-term repercussions are expected to have an influence on industry growth during the projection period. Our continuous study is enhancing our research approach to guarantee that fundamental COVID-19 concerns and potential solutions are included. The research examines COVID-19 in light of changes in consumer behaviour and demand, purchasing patterns, supply chain re-routing, market dynamics, and government involvement. Pulmonary Drug Delivery Systems Market research report considers the influence of COVID-19 on the market and includes insights, analysis, projections, and predictions.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX